A Description of Apixaban Dosing Patterns for Treatment or Prevention of Thrombotic Events in Hospitalized Patients on Dialysis

Autor: Brittany Noelle White, Megan Van Berkel Patel, Jason Ware, Tate Cutshall, Sami Sakaan, Adam Joshua Sawyer

Publikováno v: Hospital Pharmacy. 58:49-56

Introduction: Apixaban is currently the only oral direct factor Xa inhibitor approved for treatment and prevention of venous thromboembolism (VTE) in patients on hemodialysis. Exclusion of dialysis patients from major clinical trials results in presc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4af97a37311cf7e694791eba69e61f17
https://doi.org/10.1177/00185787221115311

The aftermath of amiodarone therapy: Hyperammonemia and encephalopathy

Autor: Taylor Waguespack, B. Tate Cutshall, Callee Brooks

Publikováno v: The Nurse practitioner. 47(6)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::147eb6c27a036571b3b174afbc0ba2ed
https://pubmed.ncbi.nlm.nih.gov/35604291

Evaluating Time to In-Hospital Venous Thromboembolism in Obese Patients

Autor: Navneet Upadhyay, Alexandra Tatara, Melanie Ruegger, David Putney, B. Tate Cutshall, Mobolaji Adeola

Publikováno v: Journal of Pharmacy Practice. 34:190-198

Background: Currently, no consensus approach exists for optimal venous thromboembolism (VTE) prophylaxis in obese (BMI ≥30 kg/m2) patients. Time to development of in-hospital VTE is not well studied. Objective: This study evaluates time to in-hospi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4addf3ba977434c52488b0f2c0cf0962
https://doi.org/10.1177/0897190019847002

Changing Fields-Diabetes Medications Invading the Cardiovascular Space

Autor: Lauren D. Breite, Brandon Cave, Brandon Tate Cutshall, Mackenzie Steck, Samarth P. Shah

Publikováno v: Current problems in cardiology. 46(3)

Cardiovascular disease (CVD) remains the leading cause of mortality in patients with type 2 diabetes, and treatment strategies that impact cardiovascular (CV) outcomes in this population is an area of growing interest. Pharmacologic agents that reduc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c95e77cc160884b11f0b76d845c5d34f
https://pubmed.ncbi.nlm.nih.gov/33218786

Should Pharmacies Be Included in Medication Reconciliation? A Report of Recurrent Valproic Acid Toxicity

Autor: L. Jeff Harris, Shanise Patterson, Jessica V. Rivera, Megan A. Van Berkel, Samarth P. Shah, B Tate Cutshall

Publikováno v: Clinical Practice and Cases in Emergency Medicine, Vol 1, Iss 2 (2017)
Cutshall, B. Tate; Shah, Samarth P.; Van Berkel, Megan A.; Patterson, Shanise; Harris, L. Jeff; & Rivera, Jessica V.(2017). Should Pharmacies Be Included in Medication Reconciliation? A Report of Recurrent Valproic Acid Toxicity. Clinical Practice and Cases in Emergency Medicine, 1(2). doi: 10.5811/cpcem.2016.12.33002. Retrieved from: http://www.escholarship.org/uc/item/4z99356h
Clinical Practice and Cases in Emergency Medicine

Including outpatient pharmacies in the medication reconciliation process upon hospital discharge is not commonly performed. This case highlights the consequences of a patient refilling a discontinued prescription for valproic acid (VPA). We present a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a79a6a35ff89f45ccbb33e98985d991e
https://doi.org/10.5811/cpcem.2016.12.33002